yes
Location: United States, Massachusetts, Lexington
Employees: 11-50
Total raised: $151.2M
Founded date: 2012
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 11.02.2021 | Series C | $80M | - |
| 15.10.2019 | Series B | $40.2M | - |
| 08.03.2018 | Series B | $29M | - |
| 30.06.2016 | Grant | $2M | - |
Mentions in press and media 17
| Date | Title | Description |
| 04.06.2021 | Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of CYT-0851 | |
| 12.02.2021 | Daily funding roundup - February 11th, 2021 | Zocdoc raised $150M; Modern Health landed $74M; Human Interest secured $55M; WireWheel picks up $20M Zocdoc: Zocdoc is a digital healthcare scheduling platform. Zocdoc has raised $150 million in fresh funding led by Francisco Partners. Read... |
| 11.02.2021 | Cancer biotech Cyteir raises $80M, plans to double headcount this year | Lexington biotech Cyteir Therapeutics, a startup whose method of fighting cancer involves an approach called "synthetic lethality" that blocks cancer cells' ability to repair themselves, has brought in $80 million in Series C fina... |
| 11.02.2021 | Cyteir adds $80M to steer to Phase 2 with lead cancer drug, then maybe an IPO | Lexington, Massachusetts-based Cyteir develops drugs that tap into into a genetic vulnerability of tumors. Cancer cells proliferate in part because of their ability to repair damage to their DNA. Cyteir’s drugs are called DNA damage respons... |
| 11.02.2021 | Cancer biotech Cyteir raises $80M, plans to double headcount this year | - |
| 11.02.2021 | Cyteir Therapeutics Secures $80 Million in Series C | Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing. The company will use the new funds to ad... |
| 11.02.2021 | Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program | |
| 15.10.2019 | Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing | Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an additional $40.2 million in the company's Series B financing, for a total of $75.2 mill... |
| 15.10.2019 | Cyteir Therapeutics Raises Additional $40.2M in Series B Financing | Cyteir Therapeutics, a Lexington, Mass.-based leader in the discovery and development of next-generation synthetic lethal therapies for cancer, closed an additional $40.2m in Series B financing, for a total of $75.2m in this financing. Novo... |
| 15.10.2019 | Cyteir Therapeutics Inks Additional $40.2M Series B | LEXINGTON, MA, Cyteir Therapeutics today announced the close of an additional $40.2 million in the company's Series B financing. >> Click here for more funding data on Cyteir Therapeutics >> To export Cyteir Therapeutics fun... |
Show more